Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants
- 1 November 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 15 (11) , e013676
Abstract
Background: The FUEL trial (Fontan Udenafil Exercise Longitudinal) demonstrated statistical improvements in exercise capacity following 6 months of treatment with udenafil (87.5 mg po BID). The effect of udenafil on echocardiographic measures of single ventricle function in this cohort has not been studied. Methods: The 400 enrolled participants were randomized 1:1 to udenafil or placebo. Protocol echocardiograms were obtained at baseline and 26 weeks after initiation of udenafil/placebo. Linear regression compared change from baseline indices of single ventricle systolic, diastolic and global function, atrioventricular valve regurgitation, and mean Fontan fenestration gradient in the udenafil cohort versus placebo, controlling for ventricular morphology (left ventricle versus right ventricle/other) and baseline value. Results: The udenafil participants (n=191) had significantly improved between baseline and 26 weeks visits compared to placebo participants (n=195) in myocardial performance index ( P =0.03, adjusted mean difference [SE] of changes between groups −0.03[0.01]), atrioventricular valve inflow peak E ( P =0.009, 3.95 [1.50]), and A velocities ( P =0.034, 3.46 [1.62]), and annular Doppler tissue imaging-derived peak e′ velocity ( P =0.008, 0.60[0.23]). There were no significant differences in change in single ventricle size, systolic function, atrioventricular valve regurgitation severity, or mean fenestration gradient. Participants with a dominant left ventricle had significantly more favorable baseline values of indices of single ventricle size and function (lower volumes and areas, E/e′ ratio, systolic:diastolic time and atrioventricular valve regurgitation, and higher annular s′ and e′ velocity). Conclusions: FUEL participants who received udenafil demonstrated a statistically significant improvement in some global and diastolic echo indices. Although small, the changes in diastolic function suggest improvement in pulmonary venous return and/or augmented ventricular compliance, which may help explain improved exercise performance in that cohort. Registration: URL: https://clinicaltrials.gov ; Unique Identifier: NCT02741115.Keywords
This publication has 46 references indexed in Scilit:
- Pulmonary Hypertension in Heart Failure With Preserved Ejection FractionCirculation, 2011
- PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart FailureCirculation: Heart Failure, 2011
- Pulmonary Vascular Resistance, Collateral Flow, and Ventricular Function in Patients With a Fontan Circulation at Rest and During Dobutamine StressCirculation: Cardiovascular Imaging, 2010
- Relation of Systemic Venous Return, Pulmonary Vascular Resistance, and Diastolic Dysfunction to Exercise Capacity in Patients With Single Ventricle Receiving Fontan PalliationThe American Journal of Cardiology, 2010
- The Fontan circulation: who controls cardiac output?Interactive CardioVascular and Thoracic Surgery, 2010
- Treating Heart Failure With SildenafilCongestive Heart Failure, 2009
- THE FONTAN CIRCULATIONHeart, 2005
- Serial assessment of left ventricular diastolic function after Fontan procedureHeart, 2000
- Influence of ventricular morphology on diastolic filling performance in double-inlet ventricle after the fontan procedureJACC, 1993
- Doppler assessment of pulmonary artery flow patterns and ventricular function after the Fontan operationThe American Journal of Cardiology, 1991